کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3871962 | 1598992 | 2008 | 6 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time](/preview/png/3871962.png)
PurposeProstate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting.Materials and MethodsIn September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use.ResultsThe Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials.ConclusionsWe propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which “hard” end points such as survival will be used.
Journal: The Journal of Urology - Volume 179, Issue 6, June 2008, Pages 2181–2186